Technology Request

Looking for clinical trial in dermatology field

Summary

A French company specialized in cosmetics have patented a new formulation for one of its product. The owner of the company would like to ensure properties of his product by testing it. The company is looking for a hospital department specialized in dermatology for commercial agreement with technical assistance and NDA.

Creation Date	15 July 2013
Last Update	15 July 2015
Expiration Date	14 July 2016
Reference	TRFR20130715001

Details

Description

The French company looks for a hospital or laboratory which will be able to test the new product. The objective is to measure the filmogenic effect of a new patented formulation and to prove profits for the patients (improvement of the skin, measure of spacing for eczema flare-up).

Technical Specification or Expertise Sought

Clinical dermatologists with interest in atopic topics
*Skills and accreditations to drive a clinical trial with patients suffering from eczema.

Keywords

Technology

006002008	Toxicology

Market

007004002	Health and beauty aids

NACE

C.20.4.1	Manufacture of soap and detergents, cleaning and polishing

	preparations
C.20.4.2	Manufacture of perfumes and toilet preparations

Dissemination

Send to Sector Group

Healthcare

Client

Type and Size of Organisation Behind the Profile

Industry SME <= 10

Year Established

0

Already Engaged in Trans-National Cooperation

No.

Certification Standards

ECOCERT

Languages Spoken

English
French

Client Country

France

Partner Sought

Type and Role of Partner Sought

-Type of partner sought : hospital, laboratory
-Specific area of activity of the partner : dermatology
-Task to be performed : proposal of tests for a new product

Type of Partnership Considered

Commercial agreement with technical assistance

Technology Request

Non-centrifugation based plasma sample preparation technology

Summary

A UK-based SME is looking for companies that have technology, products and expertise that would allow for plasma separation of blood samples within 15 minutes without using centrifugation and that can be used in resource limited settings. Ideally these companies will also have fluid volume control and delivery capabilities. The SME is seeking commercial agreements to manufacture or license such technology to them with technical assistance. Joint venture agreements will also be considered.

Creation Date	04 June 2015
Last Update	15 July 2015
Expiration Date	14 July 2016
Reference	TRUK20150604001

Details

Description

This UK-based biotechnology SME specialises in diagnostics and pharmacogenomics. Fully compliant with Good Clinical Laboratory Practices (GCLP) and with ISO 13485 accreditation the company provides biotechnology and pharmaceutical companies with biomarker and personalised medicine information to support their drug development programmes. The client SME also has a molecular diagnostics platform that has been developed for point-of-care use, especially in resource limited settings.

The SME wants to further develop its technology and is interested in working with companies that have expertise, technology and products that will enable plasma separation of blood samples without using centrifugation in the process. Ideally the partner company will also be able to provide fluidic volume control and volume delivery. The client SME is looking for technology and products that can achieve non-centrifugation plasma separation in a short time period and that can be used in resource limited settings. Such technologies must also be able to provide plasma samples that are compatible with downstream analysis including gene expression analysis techniques such as microarray and quantitative polymerase chain reaction (PCR).

The SME is seeking to incorporate the plasma separation technology into its existing offerings and workflows to improve their efficiency, especially in resource limited settings. To this end it would like to enter into commercial manufacturing or licensing agreements with a partner to supply the SME with this technology. In either case technical assistance would also be required from the partner to enable the SME to fully incorporate the technology. The SME would also consider a joint venture agreement should the incorporation of the plasma separation technology warrant it.

Technical Specification or Expertise Sought

The technology or product must be able to separate plasma from blood samples without using centrifugation. The technology must also ensure that the plasma samples generated using it are compatible with later gene expression analysis techniques such as PCR and microarray. It should also be able to generate plasma samples within a short time frame and be capable of being used in a resource limited setting.

Stage of Development

Already on the market

IPR Status

Patent(s) applied for but not yet granted,Patents granted

Comment Regarding IPR status

The IPR status refers to the technology being requested.

Keywords

Technology

006001006	Diagnostics, Diagnosis
006002002	Cellular and Molecular Biology
006002005	In vitro Testing, Trials

Market

005001010	Molecular diagnosis

NACE

M.72.1.1	Research and experimental development on biotechnology
M.74.9.0	Other professional, scientific and technical activities n.e.c.
Q.86.9.0	Other human health activities

Dissemination

Send to Sector Group

Healthcare

Client

Type and Size of Organisation Behind the Profile

Industry SME 50-249

Year Established

0

Already Engaged in Trans-National Cooperation

Yes

Certification Standards

ISO 13485

Languages Spoken

English

Client Country

United Kingdom

Partner Sought

Type and Role of Partner Sought

The client SME is looking for an industrial partner. The partner would be required to provide products or technology that would allow the client SME to generate plasma samples from blood without using centrifugation. The partner would also be expected to provide expertise in the use of this product or technology.

Type of Partnership Considered

License agreement
Manufacturing agreement
Commercial agreement with technical assistance
Joint venture agreement

Technology Offer

Partner sought for new drug development for diabetes therapy by means of protein kinase MST-1

Summary

The centre for biomolecular interactions of a German university is looking for a partner for diabetes drug development by means of a license agreement, research cooperation or technical cooperation agreement.

Creation Date	09 January 2015
Last Update	13 July 2015
Expiration Date	12 July 2016
Reference	TODE20150109001

Details

Description

The Centre for Biomolecular Interactions of a German university is looking for a partner for diabetes drug development.

Diabetes mellitus is a metabolic disorder which causes increased blood sugar levels. The disease destroys the insulin-producing cells of the pancreas, the beta cells of the islets of Langerhans. This causes a lack of the blood sugar-reducing hormone insulin, resulting in a chronically increased blood sugar level. More than 7 million people are affected by this disease in Germany.

Researchers of molecular diabetology of a German University have now identified a key protein, protein kinase MST-1, which is responsible for the death of these insulin-producing cells due to apoptosis (programmed cell death) and thus for the formation of the diabetes disease. This is valid for both forms of diabetes, namely the autoimmune type 1 and type 2, which depends on age and obesity.

The scientists are carrying out intensive research on the involvement of the protein kinase MST-1 in the apoptopic processes in the beta cells. MST-1 plays a key role in the stimulation of specific signal path cascades. It was possible to demonstrate in experiments that MST-1 inhibition can prevent the formation of both type 1 and type 2 diabetes. Influencing the protein kinase MST-1 is therefore a promising therapeutic objective for the development of suitable therapies to treat both forms of diabetes.

A pharmaceutical company in drug development for the therapy of type 1 and 2 diabetes is being sought. Collaboration can be arranged by license agreement, research cooperation agreement or technical cooperation agreement, depending on the contribution of the partner.

The desired outcome of a partnership is drug development that can contribute to a specific therapy for diabetes. The patent offers potential for drug development that will help to treat and to prevent the diabetes disease worldwide.

Advantages and Innovations

Protein kinase MST-1, has been identified to be responsible for the death of insulin producing cells due to apoptosis (programmed cell deaht) and thus for the formation of the diabetes disease.

It was possible to demonstrate that the targeted inhibition of the protein was able to maintain the secretions of insulin and prevent the disease from progressing.

Influencing the protein kinase MST-1 is therefore a new promising therapeutic objective for the development of suitable therapies to treat both forms of diabetes type 1 and 2.

- Clarification of the role of MST-1 in the formation of the apoptosis provides a new aim for taking an effective therapeutic approach to diabetes.
- Protection of the beta cells by inhibiting the MST-1 prevents diabetes from progressing or from arising altogether.
- The inhibition of MST-1 results in the prevention of hyperglycemia and in an improved glucose tolerance. It was possible for the first time to demonstrate this in a mouse model.
- The treatment of diabetes and its sequelae (neural injuries, circulatory disorders in the legs and feet, eye and kidney damage) lead to enormous costs for the health care system which could be reduced via early treatment and the possibility of curing the disease.
- According to the Diabetes Atlas of the International Diabetes Federation (IDF), approx. 7 million people (with a rising tendency) affected by diabetes live in Germany, 56 million in Europe, 382 million worldwide. Therefore there is major demand for suitable and efficient therapy options.
- Efficient solutions and innovative approaches to curing diabetes are currently the subject of interest of many pharmaceutical companies.

Stage of Development

Under development/lab tested

IPR Status

Patent(s) applied for but not yet granted

Comment Regarding IPR status

A worldwide patent (PCT) is applied for but not yet granted, countries are not yet selected.

Profile Origin

Private (in-house) research

Keywords

Technology

003004007	Pharmaceutics
006001016	Pharmaceutical Products / Drugs
006002002	Cellular and Molecular Biology

Market

005002001	Therapeutic services
005002004	Drug delivery and other equipment (including kidney dialysis machines)
005003002	Pharmaceuticals/fine chemicals
005006017	Internal medicine

NACE

M.72.1.1	Research and experimental development on biotechnology
M.74.9.0	Other professional, scientific and technical activities n.e.c.
N.82.9.9	Other business support service activities n.e.c.
P.85.4.2	Tertiary education

Dissemination

Send to Sector Group

Bio Chem Tech

Restrict Dissemination to Specific Countries

Albania,Republicof,Armenia,Austria,Belgium,BosniaandHerzegovina,Brazil,FederativeRepublicof,Bulgaria,Canada,Chile,China,Croatia,Cyprus,CzechRepublic,Denmark,Egypt,Estonia,Finland,France,Germany,Greece,Hungary,Iceland,India,Republicof,Ireland,Israel,Italy,Japan,Latvia,Lithuania,Luxembourg,Macedonia,TheformerYugoslavRepublicof,Malta,Mexico,Moldova,Montenegro,Morocco,Kingdomof,Netherlands,Norway,Poland,Portugal,Romania,Russia,Serbia,Slovakia,Slovenia,SouthKorea,Spain,Sweden,Switzerland,Tunisia,Turkey,Ukraine,UnitedKingdom,USA,

Client

Type and Size of Organisation Behind the Profile

University

Year Established

0

Already Engaged in Trans-National Cooperation

Yes

Languages Spoken

English
German

Client Country

Germany

Partner Sought

Type and Role of Partner Sought

- Type of partner sought: Pharmaceutical company

- Specific area of activity of the partner: Drug Development, Diabetes

- Task to be performed by the partner sought: Drug development based on the patent, cooperation in furthermore animal experiments, financial support

Type of Partnership Considered

License agreement
Technical cooperation agreement
Research cooperation agreement

Technology Offer

Novel fibros drug test model

Summary

A university spin-off SME in northern Sweden offers a new pre-clinical model for testing new anti-fibrotic and anti-inflammatory drugs. The new model shortens and simplifies the tests, lowering the cost and performs considerably better than the ones existing today. The SME is looking for partners that develop anti-fibrotic drugs or anti-inflammatory drugs, enabling them to do the testing more efficiently. The SME offers licensing of the entire concept and/or delivering test services.

Creation Date	27 April 2015
Last Update	10 July 2015
Expiration Date	09 July 2016
Reference	TOSE20150427001

Details

Description

Fibrosis contributes to approximately 40% of deaths in the industrial world and despite this huge impact on health no effective anti-fibrotic drugs are currently available on the market. Development of anti-fibrotic drugs is hampered by the lack of good and reliable pre-clinical models for testing of new drugs.

The scientists and founders of the company have developed a pre-clinical model for testing of anti-fibrotic drugs. The development of fibrosis in the model is very similar to that seen in several human conditions as it is spontaneous and occurs in several organs.

The pre-clinical model will be offered to pharmaceutical companies or other interested clients for pre-clinical testing of new anti-fibrotic drugs. The company will plan, conduct, analyze and report the results of the tests in the model and the clients will provide the substances to be tested. A discussion about licensing of the pre-clinical model is possible if a client prefer to do the tests in-house.

Advantages and Innovations

The pre-clinical model developed has several advantages over pre-clinical models available on the market today for testing of new anti-fibrotic drugs:

- Fibrosis seen in the model develops spontaneously and at a young age
- The phenotype is 100% reproducible
- Fibrosis develops in several organs
- Development of fibrosis is similar to that seen in several human conditions

Development of fibrosis in the model occurs spontaneously and at a young age. This shortens the

test protocols and makes testing faster and less expensive than testing in pre-clinical models available on the market today. The founders predict that this pre-clinical model will become the golden standard for pre-clinical testing of anti-fibrotic drugs.

Stage of Development

Available for demonstration

IPR Status

Other

Profile Origin

National R&D programme

Keywords

Technology

006001003	Clinical Research, Trials
006002004	Genetic Engineering

Market

004004	Other Genetic Engineering
004005	Molecular design
004012	Cellular and Molecular Biology
004017	Genetic Engineering

NACE

M.72.1.1	Research and experimental development on biotechnology

Dissemination

Send to Sector Group

Bio Chem Tech

Client

Type and Size of Organisation Behind the Profile

R&D Institution

Year Established

0

Already Engaged in Trans-National Cooperation

No.

Languages Spoken

English
Swedish

Client Country

Sweden

Partner Sought

Type and Role of Partner Sought

Looking for partners such as biotech companies that are developing anti-fibrotic or anti-inflammatory drugs.

The considered models for partnerships are:
1. Analysis agreement - the company conducts tests in the pre-clinical model using drugs provided by the partner.
2. License agreement - the partner buys a license from the company to use the pre-clinical model for in-house testing of substances.

Type of Partnership Considered

License agreement

Technology Offer

Material for local wounds healing based on biodegradable nanofibers

Summary

A Czech university has developed nanofiber material for local wounds healing based on biodegradable nanofibers. The material gradually degrades and bioactive agents bound to it are liberated just in affected spot. The material is also biocompatible, and non-toxic. The university is looking for partners interested in research cooperation agreement.

Creation Date	01 June 2015
Last Update	15 July 2015
Expiration Date	14 July 2016
Reference	TOCZ20150601001

Details

Description

A Czech university has developed a special, nano-based material, used in human and veterinary medicine to heal wounds. It is manufactured by way of electrospinning the sol-gel. Solution is thermally stabilized under specific conditions that ensure easy biodegradability in the future.

High specific surface of the nanofibers (tens of m2/g) allows to bind much more of the bioactive substance than in case of traditional materials that are currently used in medicine.

The novel material is biocompatible, biodegradable and non-toxic. As for biodegradation, it was tested in vitro in certain types of mocked human liquids.

The tests proved quick and easy degradation of the novel material. By way of gradual degradation it is possible to control release of therapeutic agents that are placed on the material.

Tests, carried out by certified independent lab for cytotoxicity, skin irritation and chromosomal aberration has confirmed that the material is non-toxic. In all the mentioned tests the results were comparable with results of the negative control.

Viability of tested cell lines has surpassed 95%, so the material was marked as “material without provable toxic effect”.

Bioactive substances that are bound the material are quantified by way of spectrophotometric methods and also by HPLC (high-performance liquid chromatography).

Tests of the kinetics of releasing therapeutic substances (e.g. antibiotics) are in plans.

Scientists are looking for partners interested in further research and development.

Advantages and Innovations

• Nanofibers have capabilities to imitate structures of the real tissue – this leads to better adhesion and prolilferation of the cell
• Chemical (anorganic, SiO2) nature of the material ensures inertness of the material towards a human organism
• Nanofibers have a very good porosity except for substances of certain molecular weight while permeability is ensured in both cases. The material also inhibits bacteria to infect damaged skin
• In comparison to commonly used materials, the nanofibers have notably larger specific surface and therefore they allow binding of much higher number of molecules of active ingredient.
• Biodegradability of the material is manageable so the bound active ingredient can be released locally as needed
• As the novel material is applied locally then the organism is not stressed as in the case when therapeutic agents is provided.

Stage of Development

Field tested/evaluated

Comments Regarding Stage of Development

Material is now in pre-clinical tests´ phase (in vitro a in vivo – lab animals)

IPR Status

Patents granted

Comment Regarding IPR status

Patent granted in the Czech Republic, PCT application is submitted

Profile Origin

National R&D programme

Keywords

Technology

006001014	Medical Technology / Biomedical Engineering
006001016	Pharmaceutical Products / Drugs
006001026	Medical Biomaterials
006004	Micro- and Nanotechnology related to Biological sciences

Market

005002004	Drug delivery and other equipment (including kidney dialysis machines)

NACE

Q.86.2.1	General medical practice activities
Q.86.9.0	Other human health activities

Dissemination

Send to Sector Group

Healthcare

Client

Type and Size of Organisation Behind the Profile

Industry 250-499

Year Established

1953

Turnover

1 - 10M

Already Engaged in Trans-National Cooperation

No.

Languages Spoken

English

Client Country

Czech Republic

Partner Sought

Type and Role of Partner Sought

The university seeks partner for further research and cooperation.

Type and Size of Partner Sought

University

Type of Partnership Considered

Research cooperation agreement

Technology Offer

Laser system for less traumatic surgery

Summary

Small Russian innovative company is developing the surgical instrument of next generation that is two-wave laser system, which technical parameters make possible to perform bloodless surgical operations on soft, bone and cartilage without signs of their thermal damage. The company is looking for partners for technical cooperation and joint venture agreements.

Creation Date	07 May 2015
Last Update	13 July 2015
Expiration Date	12 July 2016
Reference	TORU20150507001

Details

Description

Intraoperative bleeding is one of the most dangerous complications in surgical practice, sometimes it leads to death in a short time. In order to achieve intraoperative hemostasis electrosurgical instruments, ultrasonic, plasma and laser scalpels are used now in surgery. Despite apparent diversity of tools, there is one principle of bleeding stop which is thermal coagulation of biofabrics. Thermal coagulation of biofabrics is the process of denaturation of the protein molecules, deferred or immediate tissue necrosis. The use of lasers in surgery is based on the effect of the absorption of laser energy directly by water, or indirectly through chromophores of biofabrics. Laser radiation of near-infrared spectrum (0.9 - 2.1 μm) is poorly absorbed by water and fabric chromophores, as a result is the deep thermal damage to biofabric. CO2 laser radiation mid-IR spectrum (10.6 μm) is absorbed by water well but the laser cannot operate in a pulsed mode, which does not allow realizing high peak power per pulse, so necessary for the surgery.
Small Russian innovative company is developing the next generation of surgical instrument. It is two-wave laser system, which technical parameters make possible to perform bloodless surgical operations on soft, bone and cartilage without signs of their thermal damage. The developed laser system consists of two lasers: 1) diode-pumped Er: YAG laser provides pulse duration of 1 ms and a peak power up to 50 kW, the wavelength of 2940 nm has a maximum in the absorption spectrum of water, the incision or removal of tissue is based on the physical effect of the cold thermal ablation without damaging it. 2) Laser diode module of 405 ± 10 nm provides a pulse duration of 100 ns and a peak power up to 20 kW, the wavelength range of 405 ± 10 nm in the absorption spectrum of water is in the "spectral window" selectively and intensively as possible is absorbed by oxyhemoglobin, affecting the blood vessels prevents bleeding (selective photothermolysis).
The main purpose of the laser system is rendering of high-tech medical care: high-precision surgical operations on the brain, heart, parenchymatous organs (including transplantation), as well as bone and cartilage.
Company is looking for the industrial manufacturing enterprises producing equipment for high-tech

medicine interested in technical cooperation and strategic partnership.

Advantages and Innovations

Innovative aspect consists in simultaneous impact of radiation energy of two lasers on biofabrics. This allows getting efficient bloodless incision or evaporation of pathological tissue without thermal damage.
Advantages:
- High level of surgical safety;
- Incision of soft, bone and cartilage tissue up to 5 microns;
- Radiation energy does not cause thermal damage to tissue;
- Bleeding is completely absent during the operation;
- No risk of HIV infection, hepatitis and other diseases;
- Operating time shortens in half;
- Postoperative period is without complications and pain;
- Rehabilitation period is reduced three times;
- There is no scar tissue on the incision;
- Low cost for this class of laser system.

Stage of Development

Under development/lab tested

Comments Regarding Stage of Development

An information search was conducted (analysis of medical laser systems market, analysis of market size), patent researches were made and patents were applied for, technical task and medical and technical requirements were developed, general concept of the surgical laser system was designed, the necessary conditions for implementation of the project were created. They are laboratories including clean rooms of 1000 class for work with heterostructures. The equipment and instruments were bought and the research group was formed.

IPR Status

Patent(s) applied for but not yet granted

Profile Origin

National R&D programme

Keywords

Technology

006001004	Cytology, Cancerology, Oncology
006001014	Medical Technology / Biomedical Engineering

Market

006001004	Chemicals and materials

NACE

C.32.5.0	Manufacture of medical and dental instruments and supplies

Dissemination

Send to Sector Group

Healthcare

Client

Type and Size of Organisation Behind the Profile

Industry SME <= 10

Year Established

2012

Turnover

<1M

Already Engaged in Trans-National Cooperation

No.

Languages Spoken

English
Russian

Client Country

Russia

Partner Sought

Type and Role of Partner Sought

Industrial and research organizations
Medical equipment manufacturer, organization conducting research in the field of low-traumatic surgery
Implementation of technology

Type and Size of Partner Sought

R&D Institution,251-500,SME 51-250

Type of Partnership Considered

Technical cooperation agreement
Joint venture agreement